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Cancer is a leading cause of death worldwide and it is caused by the interaction of genomic, environmental, and lifestyle factors.
Although chemotherapy is one way of treating cancers, it also damages healthy cells and may cause severe side effects. Therefore, it
is beneficial in drug delivery in the human body to increase the proportion of the drugs at the target site while limiting its exposure
at the rest of body through Magnetic Drug Targeting (MDT). Superparamagnetic iron oxide nanoparticles (SPIONs) are derived
from polyol methods and coated with oleic acid and can be used as magnetic drug carrier particles (MDCPs) in an MDT system.
Here, we develop a mathematical model for studying the interactions between the MDCPs enriched with three different diameters
of SPIONs (6.6, 11.6, and 17.8 nm) in theMDT systemwith an implanted magnetizable stent using different magnetic field strengths
and blood velocities. Our computational analysis allows for the optimal design of the SPIONs enrichedMDCPs to be used in clinical
applications.
1. Introduction
Cancer is a leading cause of death worldwide. Its cause is
multifactorial and is linked to the interaction of genomic,
environmental, and lifestyle factors [1]. Cancer patients are
often diagnosed with localized reduction or loss of cellular
control and normalmaturationmechanisms that incorporate
excessive cell growth, loss of cell differentiation, and the abil-
ity of cancerous tissue to grow into neighbouring tissues [2,
3]. Chemotherapy is one type of cancer treatment that inhibits
the growth of, or kills, tumours. However, chemotherapy can
damage healthy cells in the human body and it has many
undesirable side effects [4]. It is therefore beneficial to alter
the distribution of drugs in the human body, increasing
the proportion of drugs at the target site while limiting
concentration and effects in the rest of body through the use
ofMagnetic Drug Targeting (MDT) [5, 6]. Similar techniques
have also been used to deliver other agents including cells [7].
MDT refers to the attachment of therapeutics tomagneti-
zable particles to concentrate them at the desired locations by
applyingmagnetic fields [8]. It includes the investigation of an
externalmagnetic field and its interactionwith biocompatible
magnetic drug carrier particles (MDCPs) [9]. Significant
difficulties in MDT are the inherently weak magnetic force
relative to the hydrodynamic forces and targeting zones
deep below the skin [10, 11]. This makes MDCP collection
problematic, because the magnetic force on a MDCP is
proportional not only to the magnitude of the magnetic field
but also to its gradient. To overcome these limitations, soft
ferromagnetic materials such as wires, seeds, and stents are
implanted into the body to increase the localized magnetic
field strength and gradient, and this technique is called
Implant Assisted Magnetic Drug Targeting (IA-MDT) [12–
15]. Different theoretical and clinical applications of IA-MDT
have been developed [16–23]. Moreover, an IA-MDT system
which uses a magnetizable stent as an implant and high
gradient magnetic separation (HGMS) in a physiologically
stretched vessel was studied with a 2D mathematical model
[24]. In this Stent Assisted Magnetic Drug Targeting (SA-
MDT) system, a ferromagnetic stent was implanted to aid
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Table 1: Saturation magnetization (𝑀
𝑠
) of the oleate-capped Fe3O4
nanoparticles with different diameters at 300K.




collection of MDCPs in an elastic tube that has similar
mechanical properties to the blood vessel and the changes in
the mechanical behaviour were analyzed under the influence
of mechanical forces generated.
There has been a growing interest in the scientific and
clinical application of MDCPs as MDT vehicles for the
development of efficient treatment strategies. A nanoparticle-
based cancer drug has been developed and the phase 1 clinical
study of cancer patients providing positive clinical evidence
for the progress of nanoparticle application is reported [25].
Superparamagnetic iron oxide nanoparticles (SPIONs) have
also been used as magnetic resonance imaging (MRI) con-
trast agents for labelling mammalian cells since their features
can be easily tailored to include targeting moieties, fluo-
rescence dyes, or therapeutic agents [26]. SPIONs can also
be taken up by the cells through endocytosis and one
particular SPION that contains ferumoxides is approved for
hepatic imaging by the US Food and Drug Administration
(FDA) [27].
The fraction of the constituting atoms on the surface of
the nanoparticles varies with the decrease in the size of the
particles (<100 nm) and this leads to significant changes in
the magnetic structure and properties of the nanophase





nanoparticles with respect to
particle diameters (6.6, 11.6, and 17.8 nm) has been previ-
ously investigated [28]. It has been reported that the largest
particles are ferromagnetic at room temperature and smaller
nanoparticles exhibit superparamagnetism with the blocking
temperatures increasing with the particle size. Saturation





different diameters at 300K is shown in Table 1.
Here, we propose SPIONs as carriers in SA-MDT system
using a magnetizable stent as an implant and focus on the
theoretical modelling of the interaction between the MDCPs
enriched with three different sizes of SPIONs (see Figure 1).
The quantity of the SPIONs included in the MDCPs is
inversely proportional to the diameter in SPIONs in each sim-
ulation.The quantity of the carrier particles at the desired site
under the influence of four different magnetic field strengths
and four different blood velocities is considered.
2. Defining the SA-MDT System
In order to optimize the size of the SPIONs in the content
of MDCPs in an SA-MDT system, a 2D mathematical model
was developed based on a previous model [18]. The mathe-
matical model geometry of the SA-MDT system comprises a
magnetizable coiled wire stent implant in close contact with
the inner wall of a biological vessel. We expand the previous
model [18] and present the next experimental challenge to
develop a clinically relevant SA-MDT system. We model the
behaviour of 𝑁 MDCPs under the influence of (i) Stokes
drag, (ii) hydrodynamic interaction forces, and (iii) magnetic
forces that account for the mutual magnetic dipole-dipole
interactions and calculated (iv) the velocity of each MDCP
and MDCPn and (v) the system performance in terms of
collection efficiency (CE) ignoring the effect of inertia and
gravity (Figure 1).
The forces acting on a given particle labeled 𝑛MDCPn are
calculated as follows.
(i) Stokes drag, ?⃗?
𝑠
𝑛
, decreases the blood velocity relative









where 𝜂blood is the viscosity of the blood, 𝑅𝑝
𝑛
is the
radius of MDCPn, and V⃗blood and V⃗𝑝
𝑛
are the veloc-
ities of the blood and MDCPn, respectively. In the
model, V⃗blood is determined by solving the appropriate
Navier–Stokes equations as previously described [15].
(ii) Hydrodynamic interaction force, ?⃗?hyd
𝑛
, is determined
as the disturbance of the MDCPn due to the move-
ment of other MDCPs in the blood flow. By consider-
ing𝑁MDCPs, the force acting onMDCPn due to the


















is the velocity of MDCPi and 𝜉𝑛𝑖 is the
modification due to the hydrodynamic interaction.
(iii) Magnetic forces acting on MDCPn, ?⃗?𝑚𝑚
𝑛
, account
for the externally applied magnetic field strength and
mutual magnetic dipole-dipole interactions between
MDCPs. Considering the 𝑁 MDCPs, each MDCP
is taken as spherical and is having a homogeneous










⋅ ∇) ?⃗?Total𝑛, (3)
where ?⃗?
𝑛
is the total magnetic moment of MDCPn
and ?⃗?Total𝑛 is the total magnetic flux acting on
MDCPn.
(iv) The velocity of MDCPn, V⃗𝑝
𝑛
, is obtained by summing
the Stokes drag, the force due to hydrodynamic inter-




















⋅ ∇) ?⃗?Total𝑛 = 0.
(4)























Figure 1: (a) Schematic of the CV used for studying the behaviour of SPIONs enriched MDCPs in SA-MDT system. (b) The modified
magnetic force acting on MDCPs enriched with three different sizes of SPIONs is modelled in the SA-MDT system using different magnetic
field strengths and blood velocities.
(v) The system performance of the model is calculated in
terms of collection efficiency (CE) and the trajectories
of MDCPn are obtained from evaluating the stream-
line functions. Consider
CE =
2𝑅vessel − 𝑦1 + 𝑦2
2𝑅vessel
100%, (5)
where 𝑅vessel is the radius of the vessel and 𝑦1 and 𝑦2
are defined by the location of the streamline at the
entrance of control volume (CV) of the last MDCPs
captured by the stent wires.
3. Results
In the current study, we present the simulation results of the
behaviour of MDCPs enriched with three different sizes of
SPIONs (diameters 6.6, 11.6, and 17.8 nm) in SA-MDT system.
We examine the effects of interactions on the CE of the
system in terms of the changes in blood velocity and applied
magnetic field strength (Table 2).
We calculate the forces due to the magnetic dipole-dipole
and hydrodynamic interactions on 𝑁 (𝑁 = 100) MDCPs
together with the blood flow velocity. Magnetic and hydrody-
namic forces acting onMDCPs as well as blood velocity were
calculated using the finite volume library OpenFOAM [29].
We create a homogeneously distributed square cloud of 100
MDCPs at the entrance of theCV, place the centre of the cloud
at boundary of the reference capture cross section, simulate
the behaviour of MDCPs at every time step considering their
agglomeration, and eventually obtain the altered trajectories
of MDCPs for calculating the CE.The number of theMDCPs
is limited to 100 and the effective initial distance between
the MDCPs at the entrance of CV is presented in Table 2 as
calculated from a previous experimental setup [18]. In our
previous studies, the number of MDCPs in the simulations
has been limited to 25 leading to close agreement with the
experimental results [18].
In order to describe the effect of different SPIONdiameter
on the content ofMDCPs, ?⃗?
𝑚𝑚
𝑛
is calculated at the entrance of
CV for eachMDCP and presented in Figure 2.The saturation





cles) [28] is presented in Table 1. The number of the SPIONs
in MDCP is inversely proportional to the diameter of the
SPIONs. Improving the content and structure of the MDCPs
and having better surface to volume ratio, we can have better
applications of MDCPs in clinical studies.
Figure 2 shows the variation inCE of the SA-MDT system
at four different applied magnetic field strengths (0.25, 0.50,
0.75, and 1 T) and four different injection fluid velocities (0.05,
0.1, 0.25, and 0.5 cm/s). The resulting collection efficiencies
derived from this mathematical model are in agreement with
previously published work [18], and with differing SPION
diameter, the system performance can differ by up to 20% in
absolute terms.
4. Discussions
We have presented SA-MTD model incorporating the
agglomeration of particles known to occur in real biological
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Table 2: Blood and material parameters used in the SA-MDT system.






T 0.25, 0.50, 0.75, 1
Angle of field direction 𝜃 — 𝜋/2
Physical properties
Temperature 𝑇 K 300
Boltzmann’s constant 𝑘
𝐵
J/K 1.38 × 1023
Permeability of vacuum 𝜇
0
Tm/A 4𝜋 × 10−7
MDCPs properties




MDCP concentration — Particle/L 4 × 1010
Density of the polymer material 𝜌pol,𝑝 kg/m
3 950





Material — — SS 430
Wire radius 𝑅wire 𝜇m 62.5
Loop separation 𝐻 cm 0.2
Number of loops 𝑁
𝑙
— 10
Coil length 𝐿 cm 2
Saturation magnetization 𝑀implant,𝑠 kA/m 1261
Magnetic susceptibility 𝑋implant,0 — 1000
Blood and vessel properties
Velocity 𝑢
0
cm/s 0.05, 0.1, 0.25, 0.5






kg/ms 1.0 × 10−3
Vessel radius 𝑅vessel cm 0.05
Magnetic material properties
Material — — Oleate-capped Fe3O4
Weight content 𝑋fm,𝑝 wt% 100
Density 𝜌fm,𝑝 kg/m
3 5000
Magnetic moment 𝑚fm,𝑝 Am
2
Saturation magnetization 𝑀fm,𝑝,𝑠 kA/m See Table 1
Diameter 𝑅fm,𝑝 nm See Table 1
systems and studied the effect of SPION diameter used in
the MDCPs using different magnetic field strengths and
blood velocities. We calculated both the dipole-dipole and
hydrodynamic interactions for 100 particles and the resulting
collection efficiencies derived from the mathematical model
are in closer agreement with our latest experimental results
[18].
We envisage that new insights obtained from the results of
our analysis may be used in prediction of efficacy of targeted
drug delivery for designing effective nanotherapeutic tools
that can translate into the clinic. The CE of the system is
increased with the higher magnetic field strength and
decreased with the higher blood velocities as expected.More-
over, the modelling of different sizes of SPIONs in a SA-MDT
system presented in this work represents a useful analytical
tool for the prediction of the efficacy of targeted drug delivery.
Our simulations indicate that size of the SPIONs in MDCPs
together with saturation magnetization of the SPIONs has
considerable effect on collection efficiency of the SA-MDT
system. The response of SA-MDT is mainly dominated by
the size of SPIONs and the saturation magnetization value of
SPIONs, and these parameters can be calibrated based on the
clinical applications of SA-MDT system using the results of
our simulation. Improvement of the fundamental models in
MDT systems may allow for the development of the more
complex models that include systems level interactions.
The presented mathematical model for the movement of
the MDCPs in the blood can be integrated with genome-
scale metabolic models (GEMs) for healthy cells/tissues [30–
33], cancers [34, 35], and cancer cell lines [36]. GEMs are
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Figure 2: CE of the SA-MDT system is plotted with different magnetic field strengths (0.25, 0.50, 0.75, and 1 T) and blood velocities (0.05,
0.1, 0.25, and 0.5 cm/s).
the compilation of biochemical reactions to define the entire
known metabolism of the cells and tissues [37, 38], and they
are reconstructed through the integration of proteomics [33,
39], transcriptomics [40–42], and metabolomics data [43].
Such integrative models can be used for discovery of novel
biomarkers as well as for identification of drug targets to
develop efficient treatment strategies for metabolism related
diseases including cancer [44].
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